AGP Picks
View all

Biopharmaceutical CMO and CRO market forecast to hit $48.79B by 2030

Nov. 6, 2026
Biopharmaceutical CMO and CRO market forecast to hit $48.79B by 2030
By AI, Created 18:00 UTC, Nov 06, 2026, AGP -

The biopharmaceutical contract manufacturing and research services market is projected to keep expanding through 2030 as drugmakers outsource more development and production work. The Business Research Company expects faster growth in biologics, cell and gene therapies, and digital CRO services to help push the market to $48.79 billion.

Why it matters: - Biopharmaceutical companies are leaning more on outside manufacturing and research partners to cut costs and shorten drug development timelines. - The market outlook points to stronger demand for specialized capacity in biologics, clinical trials and regulatory support. - The shift matters for drugmakers trying to speed products to market and for service providers building capacity in advanced therapies.

What happened: - The Business Research Company said the biopharmaceutical CMO and CRO market rose from $35.6 billion in 2025 to $38.01 billion in 2026. - The firm projects the market will reach $48.79 billion by 2030, growing at a 6.4% CAGR. - The report is titled Biopharmaceutical CMO and CRO Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The company also published a free sample report and the full market report.

The details: - CMOs handle biopharmaceutical manufacturing and production. - CROs support research and development work, including clinical trials and regulatory assistance. - The report links recent growth to biologic drug complexity, higher R&D spending, more clinical trials, biosimilar production and specialized contract service providers. - Forecast growth is tied to demand for advanced biologics manufacturing, more investment in cell and gene therapies, a broader global trial pipeline, faster speed-to-market strategies and more digitalized CRO services. - The report also expects more outsourcing of biologic manufacturing, wider demand for full-service contract research, flexible manufacturing capacity, more support for cell and gene therapy development and greater emphasis on regulatory compliance. - In 2025, North America held the largest share of the market. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The regional review also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables.

Between the lines: - The market forecast reflects a broader industry move toward outsourcing as biopharmaceutical work becomes more technical and capital intensive. - Rising R&D budgets are reinforcing demand for outside expertise and infrastructure. - Eurostat said the European Union invested about $456 billion (€389 billion) in research and development in 2023, with R&D spending equal to 2.26% of GDP, up from 2.22% the year before.

What's next: - The Business Research Company expects continued expansion through 2030 as cell and gene therapy pipelines grow and more manufacturers seek flexible capacity. - Digital CRO tools and regulatory services are likely to become more important as sponsors look to reduce development timelines and manage compliance. - Asia-Pacific's faster growth could shift more contract manufacturing and research activity toward the region.

The bottom line: - The biopharmaceutical CMO and CRO market is still expanding, but the next phase of growth looks tied to advanced therapies, outsourcing and faster drug development.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Market Forecast Analysis

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Market Forecast Analysis

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.